Drug companies do not want to market bad drugs and balance the risk of premature release against the benefits, so market incentives already discipline quality, making the government's extra screening less necessary.

causalpending

Speaker

Sam Peltzman

Evidence Quote

“they don't want to market bad drugs per se”

Source

Peltzman on Regulation 11/13/2006— EconTalk
Created: 11/11/2026, 5:13:30 AM

Your notes

Loading notes...